Treatment with Burosomab, an FGF23 antibody, is now an approved therapy for X-linked hypophosphatemic rickets and inoperable TIO, to tackle persistent hypophosphatemia due to a primary increase in FGF23 production [32]. The gene discussed is FGF23; the disease is hypophosphatemia.